Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
If symptoms persist beyond two weeks, worsen, or impair function, consult a doctor online with Apollo24|7 for evaluation.
Expert care from board-certified physicians and team with a proven track record of helping people like you
Treatment Suitability** - The clinic reserves the right to refuse or reschedule treatments if the patient is deemed unsuitable based on medical assessment, contraindications, or other relevant factors
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Women who were obese and had taken GLP-1 drugs were 30% less likely to get diagnosed with breast cancer, compared with other women who hadnt taken these medications, according to a new study published in the medical journal, JCO Oncology Practice
US$ 21.23
US$ 27.32
US$ 20.02
US$ 25.42
US$ 29.60
US$ 26.28
US$ 24.04
